Moderna’s mFlusiva: The First mRNA Flu Shot Arrives for Adults 50+

If you’re 50 or older, you may have seen a new flu vaccine on the pharmacy shelf lately – it’s called mFlusiva, and it’s the first flu shot in the U.S. that uses messenger‑RNA technology, the same platform that powered the Pfizer‑ and Moderna‑COVID‑19 shots. The idea behind mRNA vaccines is simple yet clever: instead of injecting a dead or weakened virus, you deliver a tiny snippet of genetic code that tells your cells how to make a harmless piece of the flu virus. Your immune system then learns to recognize that piece, so when the real virus shows up, it’s ready to fight.

Moderna’s mFlusiva got FDA approval in August 2026, but only for adults 50 years and older. For those aged 65 and up, the approval came with a stipulation – the company must run an additional trial to confirm the vaccine works as well as the high‑dose flu shots the CDC usually recommends for that age group. The FDA’s vaccine advisory panel voted unanimously in favor of the approval, clearing the way for pharmacies to start offering it this flu season.

How does it stack up against the standard flu jab? In a late‑stage Phase 3 trial published in the New England Journal of Medicine, more than 40,000 participants across 11 countries received either mFlusiva or a conventional dose flu vaccine. The mRNA shot prevented laboratory‑confirmed flu about 27 % more often than the traditional shot. Side‑effects were a bit more common – you might feel a sore arm, a bit of fatigue, or a mild headache – but they were generally short‑lived and not serious.

One of the biggest perks of the mRNA approach is speed. Traditional flu vaccines are grown in eggs and can take six months to manufacture, meaning manufacturers have to guess which strains will dominate the upcoming season months in advance. mFlusiva can be produced in two to three months, allowing scientists to wait longer before locking in the strain selection and potentially improving the match between vaccine and circulating viruses.

Don’t expect the mRNA flu shot to protect you against COVID‑19, though. It’s a flu‑only vaccine. Moderna does have a separate combination COVID‑flu product, but that is only approved in the European Union at the moment.

What about cost and coverage? The list price hovers around $170 per dose, though GoodRx lists some pharmacies offering it for as low as $154. Private insurers are expected to cover it, and Medicare must pay for any FDA‑approved flu vaccine, but Medicaid’s stance is still a bit murky until the CDC’s advisory committee formally recommends it.

Where can you get it? So far, CVS has already stocked the shot, and Walgreens says deliveries are on the way. Availability will vary by location, so give your local pharmacy a quick call before you head out.

Bottom line: If you’re 50 or older and want the newest technology to help keep the flu at bay, mFlusiva is an option worth discussing with your doctor. It isn’t a miracle cure, but it does offer a modest boost in protection and arrives just in time for the season.